Resverlogix Corp. Founded in 2001, the company is dedicated to providing innovative solutions in the fields of science, clinical research, and healthcare value. As pioneers in the field of epigenetics, Resverlogix is at the forefront of advancements in gene expression regulation through the inhibition of BET proteins.

Apabetalone, their groundbreaking drug discovered in 2006, has the potential to restore biological functions affected by serious conditions like cardiovascular disease. Resverlogix recently conducted a successful Phase 3 clinical trial called BETonMACE, focusing on patients with high-risk cardiovascular disease, type 2 diabetes mellitus, and low levels of high-density lipoprotein. By complementing existing treatments, apabetalone has the power to significantly improve the quality and duration of patients' lives.

With their commitment to science and a patient-centered approach, Resverlogix is revolutionizing the treatment of chronic diseases and addressing key healthcare challenges